These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12904118)

  • 1. Electronic Reporting for Clinical Drug Safety and Pharmacovigilance. 29 - 30 October 2002, Amsterdam, The Netherlands.
    Hennig R
    Expert Opin Drug Saf; 2003 Mar; 2(2):195-7. PubMed ID: 12904118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Internet and drug safety: what are the implications for pharmacovigilance?
    Cobert B; Silvey J
    Drug Saf; 1999 Feb; 20(2):95-107. PubMed ID: 10082068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacovigilance in practice].
    Spreux A; Baldin B; Chichmanian RM
    Transfus Clin Biol; 1999 Jul; 6(4):254-9. PubMed ID: 10472690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug safety and post-marketing control. Developments since the reform of the 1978 drug regulation].
    Wille H; Schönhöfer PS
    Internist (Berl); 2002 Apr; 43(4):469-70, 473-81. PubMed ID: 12053403
    [No Abstract]   [Full Text] [Related]  

  • 9. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
    Blake KV; Prilla S; Accadebled S; Guimier M; Biscaro M; Persson I; Arlett P; Blackburn S; Fitt H
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1021-9. PubMed ID: 22039593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of population-based postmarket drug risk assessment: a regulator's perspective.
    Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
    Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving paradigms in pharmacovigilance.
    Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
    Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicines for Europe - 13th Pharmacovigilance Conference (January 29, 2020 - Amsterdam, the Netherlands).
    Hamaui Cuadrado S
    Drugs Today (Barc); 2020 Feb; 56(2):165-168. PubMed ID: 32163531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of automated record linkage for postmarketing surveillance: a response to Shapiro.
    Faich GA; Stadel BV
    Clin Pharmacol Ther; 1989 Oct; 46(4):387-9. PubMed ID: 2791441
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
    Radecka A; Loughlin L; Foy M; de Ferraz Guimaraes MV; Sarinic VM; Di Giusti MD; Lesicar M; Straus S; Montero D; Pallos J; Ivanovic J; Raine J
    Drug Saf; 2018 Dec; 41(12):1285-1302. PubMed ID: 30128638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innovations for the future of pharmacovigilance.
    Almenoff JS
    Drug Saf; 2007; 30(7):631-3. PubMed ID: 17604419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obstacles to transparency over pharmacovigilance data within the EMA.
    Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Reports on Adverse Drug Reactions Related to Herbal Medicinal Products and Herbal Supplements in the Netherlands Received by the National Pharmacovigilance Centre Lareb.
    van Hunsel FPAM; van der Kooi D; van de Koppel S; Kroes BH; Woerdenbag HJ
    Drug Saf; 2022 Jun; 45(6):651-661. PubMed ID: 35608783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.